Mechanistically, the effect of anti-CTLA4 therapy against neuroblastoma tumors with induced mismatch repair deficiency is CD4+ T cell dependent, as depletion of these cells abolished the effect. The gene discussed is CTLA4; the disease is mismatch repair cancer syndrome 1.